Our main goal in this study was to determine if the interaction of sclerostin/Dkk1 coinhibition could be optimized to improve the osteoanabolic outcome over Scl‐mAb alone, which is an FDA‐approved strategy for the treatment of osteoporosis. Here, SOST is linked to osteoporosis.